Pancreatic Intraductal Papillary-Mucinous Neoplasm
NCI Definition: A usually slow-growing epithelial neoplasm with ductal differentiation that arises from the exocrine pancreas and grows mostly within the pancreatic ducts. Grossly, it is characterized by the presence of intraductal masses. Morphologically, there is proliferation of mucin-producing cells within the pancreatic ducts, intraductal accumulation of mucin, and a papillary growth pattern. It may be associated with the presence of an invasive carcinoma. It usually occurs in older patients. Signs and symptoms include epigastric pain, weight loss, jaundice, chronic pancreatitis, and diabetes mellitus. 
Pancreatic intraductal papillary-mucinous neoplasms most frequently harbor alterations in KRAS, GNAS, BRAF, TP53, and KLF4 .
KRAS Mutation, GNAS Mutation, KRAS Exon 2 Mutation, KRAS Codon 12 Missense, and GNAS R201H are the most common alterations in pancreatic intraductal papillary-mucinous neoplasm .
There are 2 clinical trials for pancreatic intraductal papillary-mucinous neoplasm, of which 2 are open and 0 are completed or closed. Of the trials that contain pancreatic intraductal papillary-mucinous neoplasm as an inclusion criterion, 2 are phase 2 (2 open).
Bl-8040, fluorouracil, and irinotecan sucrosofate are the most common interventions in pancreatic intraductal papillary-mucinous neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.